KPTI insider transactions
Karyopharm Therapeutics Inc. (KPTI) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.
Recent Form 3, 4, and 5 filings for KPTI
- Director Oliger Christy J. was granted 15,508 shares (SEC Form 4)4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
- Director Pakianathan Deepika was granted 15,508 shares (SEC Form 4)4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
- Director Schor Chen was granted 15,508 shares (SEC Form 4)4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
- Director Su Zhen was granted 15,508 shares (SEC Form 4)4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
- Director Bohlin Garen G was granted 15,508 shares, increasing direct ownership by 515% to 18,517 units (SEC Form 4)4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
- Director Greene Barry E was granted 15,508 shares, increasing direct ownership by 1,710% to 16,415 units (SEC Form 4)4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
- EVP, Chief Development Officer Poulton Stuart was granted 896 shares and sold $3,828 worth of shares (403 units at $9.50), increasing direct ownership by 0.52% to 94,821 units (SEC Form 4) (tax withholding)4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
- EVP & Chief Medical Officer Rangwala Reshma was granted 947 shares and sold $3,876 worth of shares (408 units at $9.50), increasing direct ownership by 0.96% to 56,829 units (SEC Form 4) (withholding tax)4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
- EVP & Chief Commercial Officer Cheng Sohanya Roshan was granted 947 shares and sold $3,078 worth of shares (324 units at $9.50), increasing direct ownership by 0.58% to 107,940 units (SEC Form 4) to cover withholding tax4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
- Chief Accounting Officer Abate Kristin was granted 121 shares and sold $504 worth of shares (53 units at $9.50), increasing direct ownership by 0.29% to 23,801 units (SEC Form 4) (tax liability)4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
- President and CEO Paulson Richard A. was granted 4,920 shares and sold $20,928 worth of shares (2,203 units at $9.50), increasing direct ownership by 1% to 269,747 units (SEC Form 4) to satisfy withholding tax4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
- EVP, CLO&Secretary Mano Michael was granted 700 shares and sold $2,527 worth of shares (266 units at $9.50), increasing direct ownership by 0.46% to 94,398 units (SEC Form 4) to cover withholding tax4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
- SEC Form 4 filed by Rangwala Reshma4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
- EVP & Chief Commercial Officer Cheng Sohanya Roshan sold $43,321 worth of shares (4,604 units at $9.41), decreasing direct ownership by 4% to 107,317 units (SEC Form 4)4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
- EVP, CLO&Secretary Mano Michael sold $33,178 worth of shares (3,526 units at $9.41), decreasing direct ownership by 4% to 93,964 units (SEC Form 4)4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
- EVP & Chief Medical Officer Rangwala Reshma sold $47,669 worth of shares (5,066 units at $9.41), decreasing direct ownership by 8% to 56,739 units (SEC Form 4)4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
- EVP, Chief Development Officer Poulton Stuart sold $47,998 worth of shares (5,101 units at $9.41), decreasing direct ownership by 5% to 94,328 units (SEC Form 4)4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
- President and CEO Paulson Richard A. sold $116,311 worth of shares (12,361 units at $9.41), decreasing direct ownership by 4% to 267,030 units (SEC Form 4)4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
- EVP, Chief Development Officer Poulton Stuart sold $3,262 worth of shares (378 units at $8.63), decreasing direct ownership by 0.38% to 99,429 units (SEC Form 4)4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
- President and CEO Paulson Richard A. was granted 81,060 shares, increasing direct ownership by 41% to 279,391 units (SEC Form 4)4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
- EVP, CFO & Treasurer Macomber Lori sold $10,244 worth of shares (1,626 units at $6.30), decreasing direct ownership by 2% to 85,105 units (SEC Form 4)4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
- EVP & Chief Commercial Officer Cheng Sohanya Roshan was granted 32,415 shares, increasing direct ownership by 41% to 111,921 units (SEC Form 4)4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
- EVP & Chief Medical Officer Rangwala Reshma was granted 32,415 shares, increasing direct ownership by 110% to 61,805 units (SEC Form 4)4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
- EVP, CFO & Treasurer Macomber Lori was granted 32,415 shares, increasing direct ownership by 60% to 86,731 units (SEC Form 4)4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
- EVP, CLO&Secretary Mano Michael was granted 32,415 shares, increasing direct ownership by 50% to 97,490 units (SEC Form 4)4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
- EVP, Chief Development Officer Poulton Stuart was granted 32,415 shares, increasing direct ownership by 48% to 99,807 units (SEC Form 4)4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
- Chief Accounting Officer Abate Kristin was granted 92 shares and sold $352 worth of shares (50 units at $7.03), increasing direct ownership by 0.19% to 22,622 units (SEC Form 4)4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
- Chief Accounting Officer Abate Kristin sold $1,579 worth of shares (265 units at $5.96), decreasing direct ownership by 1% to 22,580 units (SEC Form 4)4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
- Chief Accounting Officer Abate Kristin was granted 12,799 shares, increasing direct ownership by 127% to 22,845 units (SEC Form 4)4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
- EVP, Chief Development Officer Poulton Stuart was granted 39,682 shares, increasing direct ownership by 143% to 67,392 units (SEC Form 4)4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
- SVP, General Counsel&Secretary Mano Michael was granted 43,650 shares, increasing direct ownership by 204% to 65,075 units (SEC Form 4)4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
- President and CEO Paulson Richard A. was granted 114,285 shares, increasing direct ownership by 136% to 198,331 units (SEC Form 4)4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
- EVP & Chief Commercial Officer Cheng Sohanya Roshan was granted 43,650 shares, increasing direct ownership by 122% to 79,506 units (SEC Form 4)4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
- EVP, CFO & Treasurer Macomber Lori was granted 43,650 shares, increasing direct ownership by 409% to 54,316 units (SEC Form 4)4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
- Chief Accounting Officer Abate Kristin sold $2,279 worth of shares (362 units at $6.30), decreasing direct ownership by 3% to 10,046 units (SEC Form 4)4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
- President and CEO Paulson Richard A. was granted 2,800 shares and sold $8,083 worth of shares (1,257 units at $6.43), increasing direct ownership by 2% to 84,046 units (SEC Form 4)4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
- SVP, General Counsel&Secretary Mano Michael was granted 612 shares and sold $1,505 worth of shares (234 units at $6.43), increasing direct ownership by 2% to 21,425 units (SEC Form 4)4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
- EVP, Chief Development Officer Poulton Stuart was granted 888 shares and sold $2,578 worth of shares (401 units at $6.43), increasing direct ownership by 2% to 27,710 units (SEC Form 4)4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
- EVP & Chief Medical Officer Rangwala Reshma was granted 945 shares and sold $2,623 worth of shares (408 units at $6.43), increasing direct ownership by 2% to 29,390 units (SEC Form 4)4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
- EVP & Chief Commercial Officer Cheng Sohanya Roshan was granted 945 shares and sold $2,090 worth of shares (325 units at $6.43), increasing direct ownership by 2% to 35,856 units (SEC Form 4)4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
- Chief Accounting Officer Abate Kristin was granted 46 shares and sold $148 worth of shares (23 units at $6.43), increasing direct ownership by 0.22% to 10,408 units (SEC Form 4)4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
- Chief Accounting Officer Abate Kristin sold $81 worth of shares (12 units at $6.78), decreasing direct ownership by 0.13% to 9,463 units (SEC Form 4)4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
- EVP, Chief Development Officer Poulton Stuart sold $835 worth of shares (191 units at $4.37), decreasing direct ownership by 0.70% to 27,223 units (SEC Form 4)4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
- Chief Accounting Officer Abate Kristin sold $952 worth of shares (238 units at $4.00), decreasing direct ownership by 2% to 9,475 units (SEC Form 4)4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
- SEC Form 4 filed by Director Su Zhen4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
- SEC Form 4 filed by Director Pakianathan Deepika4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
- SEC Form 4 filed by Director Oliger Christy J.4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
- SEC Form 4 filed by Director Mirza Mansoor Raza4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
- SEC Form 4 filed by Director Greene Barry E4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
- SEC Form 4 filed by Director Schor Chen4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
- SEC Form 4 filed by Director Bohlin Garen G4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
- President and CEO Paulson Richard A. sold $1,680 worth of shares (236 units at $7.12), decreasing direct ownership by 0.29% to 82,503 units (SEC Form 4)4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
- EVP & Chief Medical Officer Rangwala Reshma sold $2,585 worth of shares (419 units at $6.17), decreasing direct ownership by 1% to 28,853 units (SEC Form 4)4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
- President and CEO Paulson Richard A. sold $916 worth of shares (245 units at $3.74), decreasing direct ownership by 0.30% to 82,739 units (SEC Form 4)4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
- EVP & Chief Medical Officer Rangwala Reshma sold $22,562 worth of shares (3,587 units at $6.29), decreasing direct ownership by 11% to 29,272 units (SEC Form 4)4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
- President and CEO Paulson Richard A. sold $73,555 worth of shares (11,694 units at $6.29), decreasing direct ownership by 12% to 82,984 units (SEC Form 4)4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
- EVP & Chief Commercial Officer Cheng Sohanya Roshan sold $21,669 worth of shares (3,445 units at $6.29), decreasing direct ownership by 9% to 34,314 units (SEC Form 4)4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
- EVP, Chief Development Officer Poulton Stuart sold $22,317 worth of shares (3,548 units at $6.29), decreasing direct ownership by 11% to 27,414 units (SEC Form 4)4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
- Chief Accounting Officer Abate Kristin sold $3,592 worth of shares (571 units at $6.29), decreasing direct ownership by 6% to 9,713 units (SEC Form 4)4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
- SVP, General Counsel&Secretary Mano Michael sold $17,568 worth of shares (2,793 units at $6.29), decreasing direct ownership by 12% to 21,047 units (SEC Form 4)4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)